Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Olopatadine Hydrochloride; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• At least 1 year history of allergic conjunctivitis.

• Ability to self administer ophthalmic drops.

• Ability to avoid use of disallowed medications during the entire study period and specified period prior to visit 1.

• Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

• Presence of any ocular infection.

• Confirmed diagnosis of dry eye.

• Presence of glaucoma or ocular hypertension.

• Moderate to severe asthma.

• Any severe, unstable, or uncontrolled systemic disease.

• Other protocol-defined exclusion criteria may apply.